CERo Therapeutics Holdings, Inc. Common Stock (CERO NASDAQ) stock market data APIs
$0.402
0(0%)
as of June 9, 2025
Try our APIs with
free plan!
CERo Therapeutics Holdings, Inc. Common Stock Financial Data Overview
CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies and solid tumors. The company was incorporated in 2021 and is based in South San Francisco, California.
Prev. Close
0.402
Open
0.402
High
0.4099
Low
0.3951
52 wk Range
0.395-98.6
Market Cap
4 786 K
Shares Outstanding
51 354 K
EPS
-1.5912
Beta
-0.437
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get CERo Therapeutics Holdings, Inc. Common Stock data using free add-ons & libraries
Get CERo Therapeutics Holdings, Inc. Common Stock Fundamental Data
CERo Therapeutics Holdings, Inc. Common Stock Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get CERo Therapeutics Holdings, Inc. Common Stock Earnings data
$
19.99
/mo.
What’s included:
- Latest Release: 2025-05-15
- EPS/Forecast: -5.96
Get CERo Therapeutics Holdings, Inc. Common Stock End-of-day data
EOD Historical Data package for
$
19.99
/mo.
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
CERo Therapeutics Holdings, Inc. Common Stock News
New
CERo Therapeutics, Inc. Announces Option Exercise for Additional Series D Financing
SOUTH SAN FRANCISCO, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next generatio...
Cero announces two granted U.S. patents, European patent application allowance
CERo Therapeutics (CERO) Holdings announces two previously announced U.S. patent applications have been granted by the U.S. Patent and Trademark Office, and one European patent application has been al...
CERo Therapeutics Holdings, Inc. Announces Continued Enhancement of Intellectual Property Portfolio with Two Granted U.S. Patents and European Patent Application Allowance Regarding Company’s Lead Compound CER-1236
Results in 18 Issued Patents and Allowed Patent Applications Internationally with Nine Total Patent Families SOUTH SAN FRANSCISCO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdi...
CERo Therapeutics Holdings, Inc. Doses First Patient with CER-1236 in Phase 1 Clinical Trial for Acute Myeloid Leukemia and is Advancing Through Protocol-Defined Evaluations
CERO Chief Medical Officer to discuss trial protocol in poster at the American Society for Clinical Oncology Conference The first patient has been dosed and is advancing through protocol-defined eval...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
